Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors

NCT00324987 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00324987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00324987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2008
Completion date
July 31, 2015
Enrollment
12 (actual)
Sites
192

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumor